Therapeutic role of semaglutide in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis of placebo-controlled trials with GRADE evidence assessment.

A meta-analysis of placebo-controlled randomized trials, using Cochrane RoB 2 and GRADE, so the evidence base is relatively strong. Semaglutide was associated with lower liver enzymes and roughly double the odds of NASH resolution, alongside weight and HbA1c improvements. The effect on fibrosis stage was not statistically significant, and gastrointestinal adverse events were more common, so read the results as promising but not settled.